Blueprint Medicines CORP Form 4 insider transactions

Blueprint Medicines Corporation's Chief Financial Officer, Michael Landsittel, converted all his common stock, restricted stock units, performance stock units, and stock options into cash and contingent value rights following the company's acquisition by Sanofi.

Blueprint Medicines Corporation Director Habib J. Dable disposed of all common stock and stock options on July 17, 2025, as part of the company's merger with Sanofi, receiving $129.00 per share plus a contingent value right.

Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reported the disposition of common stock and stock options, and acquisition of shares from performance units, all in connection with the company's merger with Sanofi, effective July 17, 2025.

Blueprint Medicines Director John Tsai reported the conversion of his common stock, restricted stock units, and stock options into cash and contingent value rights as part of Sanofi's acquisition of the company, effective July 17, 2025.

A Blueprint Medicines Corporation director's equity holdings, including common stock, restricted stock units, and stock options, were converted into cash and contingent value rights as part of Sanofi's acquisition of the company.

Blueprint Medicines' Chief Medical Officer, Hewes L. Becker, reported the conversion of all his equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the acquisition by Sanofi on July 17, 2025.

Lynn Seely, a director at Blueprint Medicines Corporation, disposed of all her common stock, restricted stock units, and stock options as part of Sanofi's acquisition of the company for $129.00 per share plus a contingent value right.

Blueprint Medicines Corporation has been acquired by Sanofi, leading to the conversion of Chief Scientific Officer Percy H. Carter's equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights.

Blueprint Medicines Corporation's Chief Operating Officer, Christina Rossi, converted all her equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the company's acquisition by Sanofi at $129.00 per share plus CVRs.

Blueprint Medicines Corp's Chief Executive Officer, Kate Haviland, disposed of all common stock, restricted stock units, performance stock units, and stock options as a result of Sanofi's acquisition of the company.

Blueprint Medicines Corporation's Director, Alexis Borisy, reported significant changes in beneficial ownership following the company's acquisition by Sanofi, with all shares, RSUs, and stock options converted into cash and contingent value rights.

Blueprint Medicines Corporation has been acquired by a Sanofi subsidiary through a tender offer and merger, resulting in Director Mark Alan Goldberg disposing of his common stock and stock options for cash and contingent value rights.

Blueprint Medicines Corp's President of R&D, Fouad Namouni, disposed of all beneficial ownership in the company's common stock and derivative securities following the completion of its merger with Sanofi.

Blueprint Medicines Corporation's director, Daniella Beckman, disposed of all her common stock and stock options as the company completed its merger, becoming a wholly-owned subsidiary of Sanofi.

Blueprint Medicines' EVP & Chief Legal Officer, Tracey L. McCain, reported the disposition of common stock and stock options following the company's acquisition by Sanofi for $129.00 per share plus a contingent value right.

Blueprint Medicines Corp's Chief People Officer, Debra Durso-Bumpus, disposed of all beneficial ownership in common stock and stock options following the completion of Sanofi's acquisition of the company on July 17, 2025.

Blueprint Medicines' Chief Commercial Officer, Philina Lee, reported the conversion and disposition of her equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the company's acquisition by Sanofi.

Blueprint Medicines Corporation has been acquired by Sanofi, resulting in the conversion of all outstanding common stock, restricted stock units, and stock options into cash and contingent value rights for Director Jeffrey W. Albers and other shareholders.

Blueprint Medicines' Chief Operating Officer, Christina Rossi, sold 1,172 shares of common stock on July 3, 2025, at $128.25 per share, solely to cover tax withholding obligations related to restricted stock unit vesting.

Blueprint Medicines Corporation's Chief Scientific Officer, Percy H. Carter, sold 1,051 shares of common stock at $128.25 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Blueprint Medicines Corporation Director Jeffrey W. Albers reported the acquisition of 3,902 shares of common stock through a restricted stock unit grant, increasing his beneficial ownership to 150,532 shares.

Mark Alan Goldberg, a Director at Blueprint Medicines Corp, was granted 3,902 restricted stock units valued at $128.12 per share, aligning his interests with long-term shareholder value.

Blueprint Medicines Corporation's Director, Lynn Seely, was granted 3,902 restricted stock units valued at $128.12 per unit, increasing her beneficial ownership to 17,156 shares.

Blueprint Medicines Corporation's Director, Daniella Beckman, was granted 3,902 restricted stock units valued at $128.12 per share, increasing her direct beneficial ownership to 14,744 shares.

Blueprint Medicines Corporation's Director, Alexis Borisy, has been granted 3,902 restricted stock units (RSUs) valued at $128.12 per share, increasing his beneficial ownership to 78,062 shares.

Blueprint Medicines Corporation Director Habib J Dable acquired 3,902 shares of common stock through a restricted stock unit grant on June 18, 2025, increasing his beneficial ownership to 12,644 shares.

Blueprint Medicines Corporation's Director, Lonnel Coats, was granted 3,902 restricted stock units valued at $12,812, vesting by June 2026.

Blueprint Medicines Corporation's Director, John Tsai, has been granted 3,902 restricted stock units (RSUs) valued at $128.12 per share, aligning his interests with shareholders.

Percy H. Carter, Chief Scientific Officer and Director of Blueprint Medicines Corp, sold 2,659 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Jeffrey W. Albers, a Director at Blueprint Medicines Corp, exercised 5,000 stock options and subsequently sold an equal number of shares on May 27, 2025, as part of a pre-arranged trading plan.